treatment approaches for asct-eligible myeloma patients in the frontline
Published 3 years ago • 38 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
0:59
treatment approaches for transplant-eligible and transplant-ineligbile myeloma patients
-
1:31
bispecific antibodies in the treatment pipeline for myeloma in the uk
-
3:02
optimal treatment strategies for multiple myeloma
-
3:57
imroz: isa-vrd vs vrd for transplant-ineligible newly diagnosed multiple myeloma
-
1:42
treatment options for transplant-ineligble myeloma patients: the promise of combination therapies
-
4:46
does asct still have a place in myeloma treatment?
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
11:41
multiple myeloma - signs and symptoms, pathophysiology, treatment
-
3:41
can novel immunotherapies cure multiple myeloma?
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
1:55
asct remains at the forefront of multiple myeloma therapy
-
2:59
real world tandem asct for high risk mm
-
4:20
ixazomib or lenalidomide post-asct in ndmm
-
1:31
bites in myeloma – when and who?
-
1:48
cassiopeia: update on daratumumab maintenance for multiple myeloma
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
1:52
upfront asct for newly diagnosed multiple myeloma: double vs. single transplant
-
1:28
mrd negativity in myeloma patients undergoing maintenance therapy
-
1:44
optimal treatment sequencing in multiple myeloma
-
3:34
maintenance therapy following salvage asct for multiple myeloma
-
1:10
latest developments in the treatment of emd in myeloma
-
1:53
the future of multiple myeloma treatment